{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:45:54Z","timestamp":1792097154736,"version":"4.4.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Although adults with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL) may achieve a measurable residual disease-negative (MRD-) complete response (CR) after frontline treatment and blinatumomab (blina) consolidation, survival outcomes are heterogeneous, and known prognostic factors are limited. We conducted a retrospective, multicenter study of 81 adults with Ph+ B-ALL in MRD- (&amp;lt;10-4) CR1 after blina consolidation and stratified them by pre-blina MRD status as determined by multiparametric flow cytometry (flow). Patients who were pre-blina flow MRD- (n = 56) and flow MRD+ (n = 25) had similar baseline characteristics. With a median follow-up of 31.0 months, pre-blina flow MRD- patients had superior disease-free (DFS) and overall survival (OS) on univariate (p = 0.049 and p = 0.045, respectively) and multivariable analyses (HR 0.27, 95% CI 0.08-0.87 and HR 0.17, 95% CI 0.03-0.90, respectively) relative to pre-blina flow MRD+ patients. Inferior DFS was seen with the IKZF1-plus genotype (HR 3.51, 95% CI 1.08-11.44) and extramedullary disease at diagnosis (HR 3.90, 95% CI 1.19-12.73). In exploratory analyses, pre-blina flow MRD+ status remained associated with inferior DFS (p = 0.0005) and OS (p &amp;lt; 0.0001) for patients who did not receive a subsequent hematopoietic cell transplant (HCT) in CR1, but not in patients who did (p = 0.55 and p = 0.99, respectively). In summary, flow MRD+ status before blina consolidation was associated with inferior survival in patients with Ph+ B-ALL in CR1 despite subsequent clearance, and consolidative HCT may reduce this prognostic effect.<\/jats:p>","DOI":"10.1182\/bloodadvances.2026020724","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:09:53Z","timestamp":1792094993000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5251-5299","authenticated-orcid":false,"given":"Benjamin F.","family":"Frost","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-6732","authenticated-orcid":false,"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie W.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-8245","authenticated-orcid":false,"given":"Eric S","family":"Winer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-1919","authenticated-orcid":false,"given":"Virgina O","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Hergott","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mass General Brigham, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-398X","authenticated-orcid":false,"given":"Kuo-Kai","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-2773","authenticated-orcid":false,"given":"Meira","family":"Yisraeli Salman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leora","family":"Boussi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-1253","authenticated-orcid":false,"given":"Natalia","family":"Tijaro Ovalle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-9117","authenticated-orcid":false,"given":"Mark B","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Brunner","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-9403","authenticated-orcid":false,"given":"Hanno","family":"Hock","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-6221","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Narayan","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-215X","authenticated-orcid":false,"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,15]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020724\/2595531\/bloodadvances.2026020724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020724\/2595531\/bloodadvances.2026020724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:09:53Z","timestamp":1792094993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026020724\/571579\/Flow-MRD-pre-blinatumomab-consolidation-despite"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020724","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"bloodadvances.2026020724"}}